New drug combo aims to tame rare blood cancers

NCT ID NCT05936359

Recruiting now Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called INCA033989, alone or with an existing drug ruxolitinib, in 225 people with myeloproliferative neoplasms (a group of blood cancers). The main goal is to check safety and find the best dose. Participants must have a specific genetic mutation (CALR) and be willing to have bone marrow tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

INCA033989 and ruxolitinib

What this could lead to

If successful, this could lead to a new treatment option for myeloproliferative neoplasms, potentially improving symptom control and reducing spleen size.

What could go wrong

This is an early Phase 1 trial focused on safety and dosing, so it is not yet known if the drug works. Side effects and limited effectiveness are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential thrombocythemia Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOPROLIFERATIVE NEOPLASMS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Aou Policlinico S. Orsola-Malpighi
RECRUITING

Bologna, 40138, Italy
Azienda Ospedaliero-Universitaria Careggi (Aouc)
RECRUITING

Florence, 50134, Italy
Chu Nimes
RECRUITING

Nîmes, 30029, France
Fondazione Irccs Ca Granda Ospedale Maggiore
RECRUITING

Milan, 20122, Italy
Guys and St Thomas Nhs Foundation Trust
RECRUITING

London, SE1 9RT, United Kingdom
Hopital Maisonneuve-Rosemont, Montreal, Qc
RECRUITING

Montreal, Quebec, H1T 2M4, Canada
Hospital Saint Louis
RECRUITING

Paris, 75010, France
Hospital Universitari I Politecnic La Fe
RECRUITING

Valencia, 46026, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Institut Bergonie
RECRUITING

Bordeaux, 33076, France
Institut Gustave Roussy
RECRUITING

Villejuif, 94805, France
Kagoshima University Hospital
RECRUITING

Kagoshima, 890-8520, Japan
Mie University Hospital
RECRUITING

Tsu, 514-0001, Japan
National Cancer Center Hospital East
RECRUITING

Chiba-ken, 277-0882, Japan
Nippon Medical School Hospital
RECRUITING

Tokyo, 113-8603, Japan
Odense University Hospital
WITHDRAWN

Odense C, 05000, Denmark
Osaka Metropolitan University Hospital
RECRUITING

Osaka, 545-8586, Japan
Peter Maccallum Cancer Centre
RECRUITING

Melbourne, Victoria, 03000, Australia
Princess Margaret Cancer Center
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Royal Adelaide Hospital
RECRUITING

Adelaide, South Australia, 05000, Australia
Royal Brisbane and Women'S Hospital
RECRUITING

Herston, Queensland, 04029, Australia
Sjaellands Universitetshospital
RECRUITING

Roskilde, 04000, Denmark
The Alfred Hospital
RECRUITING

Melbourne, Victoria, 03004, Australia
The Christie Nhs Foundation Trust Uk
RECRUITING

Manchester, M20 4BV, United Kingdom
Universitatsklinikum Halle (Saale)
RECRUITING

Halle, 06120, Germany
University Medical Center Rwth Aachen
RECRUITING

Aachen, 52074, Germany
University of Oxford
RECRUITING

Oxford, OX3 7LE, United Kingdom
Universitätsklinikum Ulm
RECRUITING

Ulm, 89081, Germany
Vejle Hospital
RECRUITING

Vejle, 07100, Denmark